134 related articles for article (PubMed ID: 30026328)
1. The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.
Spiegelberg D; Mortensen AC; Lundsten S; Brown CJ; Lane DP; Nestor M
Cancer Res; 2018 Sep; 78(17):5084-5093. PubMed ID: 30026328
[TBL] [Abstract][Full Text] [Related]
2. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
[TBL] [Abstract][Full Text] [Related]
3. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
4. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.
Ling X; Xu C; Fan C; Zhong K; Li F; Wang X
Cancer Res; 2014 Dec; 74(24):7487-97. PubMed ID: 25512388
[TBL] [Abstract][Full Text] [Related]
5. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
7. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
8. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
9. Targeting Mdmx to treat breast cancers with wild-type p53.
Haupt S; Buckley D; Pang JM; Panimaya J; Paul PJ; Gamell C; Takano EA; Lee YY; Hiddingh S; Rogers TM; Teunisse AF; Herold MJ; Marine JC; Fox SB; Jochemsen A; Haupt Y
Cell Death Dis; 2015 Jul; 6(7):e1821. PubMed ID: 26181202
[TBL] [Abstract][Full Text] [Related]
10. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
11. The Stapled Peptide PM2 Stabilizes p53 Levels and Radiosensitizes Wild-Type p53 Cancer Cells.
Mortensen ACL; Spiegelberg D; Brown CJ; Lane DP; Nestor M
Front Oncol; 2019; 9():923. PubMed ID: 31616635
[TBL] [Abstract][Full Text] [Related]
12. An Update on MDMX and Dual MDM2/X Inhibitors.
Espadinha M; Barcherini V; Lopes EA; Santos MMM
Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
[TBL] [Abstract][Full Text] [Related]
13. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
14. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
15. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin enhances the radiosensitivity of p53‑deficient cells via inhibition of mouse double minute 2 homolog.
Lee JY; Kim MS; Ju JE; Lee MS; Chung N; Jeong YK
Int J Oncol; 2018 Jan; 52(1):211-218. PubMed ID: 29115437
[TBL] [Abstract][Full Text] [Related]
17. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
18. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
19. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 in the response to radiation.
Perry ME
Mol Cancer Res; 2004 Jan; 2(1):9-19. PubMed ID: 14757841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]